Clinical Research Details Clinical Research Gilead GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/ Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children Study Description To test the safety, effectiveness, and pharmacokinetics of a new HIV medication, GS-9883. Participants will receive the new medication for 48 weeks. During that time, participants will have clinic visits, physical exams, and blood tests at Screening, Day 1, Weeks 1, 2, 4, 8, 12, 16, 24, 36, 48, and a 30 day follow-up visit. Investigators Nizar F. Maraqa, M.D. Pediatrics Ayesha Mirza, M.D. Pediatrics Mobeen H. Rathore, M.B.B.S. (M.D.), CPE, FACPE, FIDSA, FAAP Pediatrics